APA
Gopalakrishnan V., Spencer C. N., Nezi L., Reuben A., Andrews M. C., Karpinets T. V., Prieto P. A., Vicente D., Hoffman K., Wei S. C., Cogdill A. P., Zhao L., Hudgens C. W., Hutchinson D. S., Manzo T., Petaccia de Macedo M., Cotechini T., Kumar T., Chen W. S., Reddy S. M., Szczepaniak Sloane R., Galloway-Pena J., Jiang H., Chen P. L., Shpall E. J., Rezvani K., Alousi A. M., Chemaly R. F., Shelburne S., Vence L. M., Okhuysen P. C., Jensen V. B., Swennes A. G., McAllister F., Marcelo Riquelme Sanchez E., Zhang Y., Le Chatelier E., Zitvogel L., Pons N., Austin-Breneman J. L., Haydu L. E., Burton E. M., Gardner J. M., Sirmans E., Hu J., Lazar A. J., Tsujikawa T., Diab A., Tawbi H., Glitza I. C., Hwu W. J., Patel S. P., Woodman S. E., Amaria R. N., Davies M. A., Gershenwald J. E., Hwu P., Lee J. E., Zhang J., Coussens L. M., Cooper Z. A., Futreal P. A., Daniel C. R., Ajami N. J., Petrosino J. F., Tetzlaff M. T., Sharma P., Allison J. P., Jenq R. R. & Wargo J. A. (20180410). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. : Science (New York, N.Y.).
Chicago
Gopalakrishnan V, Spencer C N, Nezi L, Reuben A, Andrews M C, Karpinets T V, Prieto P A, Vicente D, Hoffman K, Wei S C, Cogdill A P, Zhao L, Hudgens C W, Hutchinson D S, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen W S, Reddy S M, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen P L, Shpall E J, Rezvani K, Alousi A M, Chemaly R F, Shelburne S, Vence L M, Okhuysen P C, Jensen V B, Swennes A G, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman J L, Haydu L E, Burton E M, Gardner J M, Sirmans E, Hu J, Lazar A J, Tsujikawa T, Diab A, Tawbi H, Glitza I C, Hwu W J, Patel S P, Woodman S E, Amaria R N, Davies M A, Gershenwald J E, Hwu P, Lee J E, Zhang J, Coussens L M, Cooper Z A, Futreal P A, Daniel C R, Ajami N J, Petrosino J F, Tetzlaff M T, Sharma P, Allison J P, Jenq R R and Wargo J A. 20180410. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. : Science (New York, N.Y.).
Harvard
Gopalakrishnan V., Spencer C. N., Nezi L., Reuben A., Andrews M. C., Karpinets T. V., Prieto P. A., Vicente D., Hoffman K., Wei S. C., Cogdill A. P., Zhao L., Hudgens C. W., Hutchinson D. S., Manzo T., Petaccia de Macedo M., Cotechini T., Kumar T., Chen W. S., Reddy S. M., Szczepaniak Sloane R., Galloway-Pena J., Jiang H., Chen P. L., Shpall E. J., Rezvani K., Alousi A. M., Chemaly R. F., Shelburne S., Vence L. M., Okhuysen P. C., Jensen V. B., Swennes A. G., McAllister F., Marcelo Riquelme Sanchez E., Zhang Y., Le Chatelier E., Zitvogel L., Pons N., Austin-Breneman J. L., Haydu L. E., Burton E. M., Gardner J. M., Sirmans E., Hu J., Lazar A. J., Tsujikawa T., Diab A., Tawbi H., Glitza I. C., Hwu W. J., Patel S. P., Woodman S. E., Amaria R. N., Davies M. A., Gershenwald J. E., Hwu P., Lee J. E., Zhang J., Coussens L. M., Cooper Z. A., Futreal P. A., Daniel C. R., Ajami N. J., Petrosino J. F., Tetzlaff M. T., Sharma P., Allison J. P., Jenq R. R. and Wargo J. A. (20180410). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. : Science (New York, N.Y.).
MLA
Gopalakrishnan V, Spencer C N, Nezi L, Reuben A, Andrews M C, Karpinets T V, Prieto P A, Vicente D, Hoffman K, Wei S C, Cogdill A P, Zhao L, Hudgens C W, Hutchinson D S, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen W S, Reddy S M, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen P L, Shpall E J, Rezvani K, Alousi A M, Chemaly R F, Shelburne S, Vence L M, Okhuysen P C, Jensen V B, Swennes A G, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman J L, Haydu L E, Burton E M, Gardner J M, Sirmans E, Hu J, Lazar A J, Tsujikawa T, Diab A, Tawbi H, Glitza I C, Hwu W J, Patel S P, Woodman S E, Amaria R N, Davies M A, Gershenwald J E, Hwu P, Lee J E, Zhang J, Coussens L M, Cooper Z A, Futreal P A, Daniel C R, Ajami N J, Petrosino J F, Tetzlaff M T, Sharma P, Allison J P, Jenq R R and Wargo J A. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. : Science (New York, N.Y.). 20180410.